Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 Oncology, Respectively
Portfolio Pulse from Benzinga Newsdesk
Xoma has acquired the royalty and milestone rights for two assets from LadRx, including Arimoclomol for Niemann-Pick disease type C and Aldoxorubicin for Phase 2 oncology, for $5 million.
June 22, 2023 | 11:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xoma's acquisition of royalty and milestone rights for Arimoclomol and Aldoxorubicin from LadRx for $5M could potentially boost its revenue and portfolio.
Xoma's acquisition of the royalty and milestone rights for Arimoclomol and Aldoxorubicin from LadRx for $5 million directly impacts the company's portfolio and potential revenue streams. The acquisition targets orphan disease Niemann-Pick disease type C and Phase 2 oncology, which could lead to increased revenue and growth for Xoma.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100